Route 92 key facts
as of Oct 2026- Developer of neurovascular intervention devices designed to improve outcomes for patients with vascular conditions in the brain.
- Route 92 is valued at approximately $307.5M as of Oct 2026 (last reported valuation).
- It has raised $293.6M; the latest was Later Stage VC ($50.0M) in Jan 2026.
- Notable investors include Norwest, Novo Holdings, InnovaHealth Partners, Sectoral Asset Management, The Vertical Group — 6 tracked in total.
- Status: Privately Held (backing).
Route 92's last reported valuation, Jan 2026. Nothing priced has surfaced since.
- ·Watch Route 92: the Monday email on marks, rounds and moves
Route 92 funding rounds
No funding rounds for Route 92 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Route 92 valuation
Route 92's last reported valuation was $308 million in Jan 2026. No priced round, secondary trade or fund mark has surfaced since.
Route 92 investors
6 investors are on record for Route 92, including Norwest, Novo Holdings, InnovaHealth Partners and Sectoral Asset Management.
About Route 92
Developer of neurovascular intervention devices designed to improve outcomes for patients with vascular conditions in the brain. The company offers advanced catheter systems and reperfusion technology for precise navigation and clot removal, enabling healthcare providers to perform complex neuro-intervention procedures with improved access and treatment efficiency.
- Sector
- Healthcare
- HQ
- West Jordan, UT, United States
- Founded
- 2015
- Employees
- 189
- Website
- route92medical.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.